TrialThe Lancet. Oncology2024

Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study.

Mohamad E Allaf et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.